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Abstract
Patients suffering from bone metastases of follicular thyroid
carcinoma (FTC) have a poor prognosis because of the lack
of effective treatment strategies. The overexpression of
epidermal growth factor receptor (EGFR) associated with
increased vascularity has been implicated in the pathogen-
esis of FTC and subsequent bone metastases. We hypothe-
sized that inhibiting the phosphorylation of the EGFR and
vascular endothelial growth factor receptor (VEGFR) by
AEE788, a dual tyrosine kinase inhibitor of EGFR and
VEGFR, in combination with paclitaxel would inhibit
experimental FTC bone lesions and preserve bone structure.
We tested this hypothesis using the human WRO FTC cell
line. In culture, AEE788 inhibited the EGF-mediated phos-
phorylation of EGFR, VEGFR2, mitogen-activated protein
kinase, and Akt in culture. AEE788, alone and in combina-
tion with paclitaxel, inhibited cell growth and induced
apoptosis. When WRO cells were injected into the tibia of
nude mice, tumor and endothelial cells within the lesions
expressed phosphorylated EGFR, VEGFR, Akt, and mitogen-
activated protein kinase that were inhibited by the oral
administration of AEE788. Therapy consisting of orally given
AEE788 and i.p. injected paclitaxel induced a high level of
apoptosis in tumor-associated endothelial cells and tumor
cells with the inhibition of tumor growth in the bone and the
preservation of bone structure. Collectively, these data show
that blocking the phosphorylation of EGFR and VEGFR with
AEE788 combined with paclitaxel can significantly inhibit
experimental human FTC in the bone of nude mice. (Cancer
Res 2005; 65(11): 4716-27)
Introduction
Thyroid cancer is the most common endocrine neoplasm in the
United States (1). The incidence of thyroid cancer has been
growing at an alarming rate of 3% annually (2). Histologically, 94%
of thyroid carcinomas are well differentiated; this group includes
papillary thyroid carcinomas and follicular thyroid carcinomas
(FTC; ref. 3). Of the well-differentiated thyroid cancers, FTC
accounts for 10% to 32% of cases (4, 5).
Although differentiated thyroid cancers are associated with a
favorable long-term survival, the prognosis worsens dramatically
for patients with distant metastases (6). Whereas the 20-year
disease-specific survival rate in patients with differentiated thyroid
cancer exceeds 90%, the 10-year survival rate following the
detection of bone metastases is <20% (7). Although patients with
FTC rank second in survival rates behind those with papillary
thyroid cancer, patients with FTC face an increased risk of
developing metastases in the lung and bone (8). In fact, metastases
from FTC occur earlier and are more aggressive than those from
papillary thyroid cancer (5). At diagnosis, bone metastasis is
present in f10% to 30% of patients with FTC (9).
In addition to a decreased survival, patients with bone
metastases from FTC have marked morbidity associated with
severe pain, pathologic fractures, life-threatening hypercalcemia,
and spinal cord compression (10). The current palliative options for
bone metastasis include chemotherapy (6), external radiation
therapy (11), arterial embolization (12), and radioactive iodine (13),
but none of these modalities has thus far been effective in slowing
the progression of the disease (14). Surgical management of bone
lesions includes the prophylactic stabilization of impending
fractures or the fixation of actual fractures with hardware or
prosthetic devices (15). However, metastatic follicular cancer is
almost invariably multifocal, involving several bones, hence
preventing complete surgical resection (16, 17). Clearly, new treat-
ment strategies for patients with FTC bone metastasis are urgently
needed.
Among the potential therapeutic targets in the management of
FTC bone metastasis is the epidermal growth factor (EGF)/EGF
receptor (EGFR) pathway. The EGF and EGFR are overexpressed in
thyroid carcinomas in comparison with normal thyroid tissue (18).
EGF stimulates the growth, proliferation, and invasion of FTC cells
and the blockade of EGFR signaling decreases the growth and
invasion of FTC cells in vitro (19). In fact, high expression of EGFR
is associated with poor prognosis in thyroid tumors (18). The
coexpression of EGF and EGFR is also associated with bone
metastasis of FTC (20).
Angiogenesis is another important potential therapeutic target
for the treatment of FTC-induced bone metastasis. Angiogenesis,
the formation of new blood vessels, plays an integral part in the
pathogenesis and spread of differentiated thyroid cancer. Actually,
FTC is the most angiogenesis-dependent tumor of the thyroid
gland (21). One of the major proangiogenic factors in thyroid
tumors is vascular endothelial growth factor (VEGF; ref. 22). The
level of VEGF mRNA and protein is associated with mitogenic
Requests for reprints: Jeffrey N. Myers, Department of Head and Neck Surgery,
The University of Texas M.D. Anderson Cancer Center, Unit 441, 1515 Holcombe
Boulevard, Houston, TX 77030-4009. Phone: 713-792-6920; Fax: 713-794-4662; E-mail:
jmyers@mdanderson.org.
I2005 American Association for Cancer Research.
Cancer Res 2005; 65: (11). June 1, 2005 4716 www.aacrjournals.org
Research Article
Research. 
on April 14, 2017. © 2005 American Association for Cancercancerres.aacrjournals.org Downloaded from 
activity and tumorigenic potential by FTC cell lines (23). The
overexpression of VEGF in differentiated thyroid cancer has been
correlated with poor prognosis (4, 24), increased risk of recurrence,
and greater probability of metastasis (25) as well as increased
microvessel density (MVD) with decreased disease-free survival in
thyroid carcinomas (26). On the other hand, the inhibition of VEGF
production or VEGFR phosphorylation has been shown to reduce
the growth of FTC xenografts (21, 27–29).
These data suggest that the blockade of both EGFR and VEGFR
kinase activities and their respective downstream targets [such as
Akt and mitogen-activated protein kinase (MAPK)] can offer an
attractive approach for the treatment of FTC bone metastasis.
NVP-AEE788 (AEE788), a member of the 7H-pyrrolo[2,3-d] class of
pyrimidines, is a novel, orally available dual specific tyrosine kinase
inhibitor of the ErbB (EGFR) and VEGFR receptors (30). The
efficacy of AEE788 against a variety of tumors (breast, lung,
bladder, and squamous cell carcinoma of the oral cavity) has been
verified both in vitro and in vivo (30, 31).
We hypothesized that inhibiting the phosphorylation of the
EGFR and VEGFR with AEE788 in combination with paclitaxel
should inhibit the growth of experimental FTC bone lesions, thus
preserving the bone structure.
In the present study, we determined whether EGFR, VEGFR, and
two of their downstream signaling targets, Akt and MAPK, are
overexpressed in FTC. We evaluated the effects of AEE788, given
alone or with paclitaxel, on the phosphorylation of these kinases,
leading to cell growth arrest and apoptosis in vitro . We also tested
whether the administration of AEE788, alone or in combination
with paclitaxel, to nude mice harboring the human FTC cells
implanted in the bone marrow of the tibia would block the EGFR
and VEGFR signaling pathways and inhibit the progressive growth
and bone lysis.
Materials and Methods
Cell lines and culture conditions. To study the biology of bone
metastasis in FTC, we used the well-established human FTC cell line WRO
(32). To assess the levels of the EGFR family of receptors in human thyroid
cancer, we used the following cell lines: ARO, DRO, K18, K4, C643, Hth74
(anaplastic thyroid carcinoma), and NPA187 (papillary thyroid cancer). All
cell lines were maintained as monolayer cultures in DMEM supplemented
with 10% fetal bovine serum (FBS), nonessential amino acids, sodium
pyruvate, L-glutamine, a 2-fold vitamin, and penicillin-streptomycin (all
from Life Technologies, Inc., Grand Island, NY). Cell cultures were
maintained and incubated as described previously (33).
Reagents. AEE788 (30), PKI166 (33), and PTK787 (28) were synthesized
and generously provided by Novartis Pharma AG (Basel, Switzerland). For
use in vitro , all three compounds were dissolved in DMSO (Sigma-Aldrich
Corp., St. Louis, MO) to a concentration of 20 mmol/L and further diluted to
an appropriate final concentration in DMEM. DMSO in the final solution
did not exceed 0.1% (v/v). For oral administration, AEE788 was dissolved in
90% polyethylene glycol 300 plus 10% 1-methyl-2-pyrrolidinone to a
concentration of 6.25 mg/mL and given to mice at a concentration of
50 mg/kg thrice weekly (30). The AEE788 solution was prepared just before
being given to mice. Paclitaxel (Mead Johnson, Princeton, NJ) was diluted in
HBSS to a final concentration of 1 mg/mL and given i.p. at 200 Ag once
weekly, a dosing regimen that was chosen based on results of previous
studies at our institution (34).
For immunohistochemistry and Western blot analysis, the following
antibodies were used: polyclonal rabbit anti-EGF, anti-VEGF, anti-EGFR,
anti-VEGFR2, and anti–activated EGFR (Santa Cruz Biotechnology, Santa
Cruz, CA); anti-HER1 (Neomarkers, Fremont, CA); anti–activated VEGFR2
(Oncogene, Cambridge, MA); monoclonal rabbit anti–activated Akt and
mouse anti–activated MAPK (Cell Signaling, Beverly, MA); rabbit Akt and
mouse MAPK (Cell Signaling); rat anti-mouse CD31/platelet/endothelial cell
adhesion molecule-1 (PECAM-1) and rat anti-mouse CD31 peroxidase-
conjugated rat anti-mouse IgG (PharMingen, San Diego, CA); mouse anti–
proliferating cell nuclear antigen (anti-PCNA) clone PC-10 (DAKO A/S,
Copenhagen, Denmark); peroxidase-conjugated F(abV)2 goat anti-rabbit IgG
F(abV)2, peroxidase-conjugated rat anti-mouse IgG F(abV)2 fragment,
Affinipure Fab fragment goat anti-mouse IgG, peroxidase-conjugated goat
anti-rat IgG, and Texas red–conjugated goat anti-rat IgG (Jackson Research
Laboratories, West Grove, CA); peroxidase-conjugated rat anti-mouse IgG2a
(Serotec; Harlan Bioproducts for Science, Inc., Indianapolis, IN); Alexa Fluor
594–conjugated goat anti-mouse IgG, Alexa Fluor 594–conjugated goat anti-
rabbit IgG, and Alexa Fluor 488–conjugated goat anti-rabbit IgG (Molecular
Probes, Eugene, OR); horseradish peroxidase–conjugated donkey anti-rabbit
IgG (Amersham, Buckinghamshire, United Kingdom); and sheep anti-mouse
and human IgG (Sigma-Aldrich). Other reagents were Hoechst dye 3342
(molecular weight, 615.9; Hoechst, Warrington, PA), stable 3,3V-diamino-
benzidine (Research Genetics, Huntsville, AL), 3-amino-9-ethylcarbazole
(BioGenex Laboratories, San Ramon, CA), and Gill’s hematoxylin (Sigma-
Aldrich). Prolong solution was purchased from Molecular Probes and
pepsin was from Biomeda (Foster City, CA).
Propidium iodide (PI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) were both purchased from Sigma-Aldrich. Stock
solutions were prepared by dissolving 1 mg of each compound in 1 mL PBS
and filtering the solution to remove particles. The solution was protected
from light, stored at 4jC, and used within 1 month.
Measurement of cell proliferation. The antiproliferative activity of
AEE788 on WRO cells growing in culture was determined using the
tetrazolium-based colorimetric (MTT) assay. Specifically, 4  103 cells were
plated for 24 hours into a 96-well plate. Cells were washed twice using 2%
FBS medium and incubated for 72 hours with AEE788. The cells were then
incubated for 2 hours in medium containing MTT and then lysed in DMSO.
The conversion of MTT to formazan by metabolically viable cells was
monitored by a 96-well microtiter plate reader at an absorbance of 570 nm
(Dynatech, Inc., Chantilly, VA).
Measurement of cell death. The WRO cells were plated at a density of
3  105 cells per well in six-well plates (Costar, Cambridge, MA) and
maintained in 10% FBS medium overnight. The next day, the cells were
washed twice and maintained in 2% FBS medium before treatment with
AEE788 and paclitaxel. Seventy-two hours later, PI staining of hypodiploid
DNA was used to determine the extent of cell death. The treated cells were
resuspended in Nicoletti buffer [50 mg/mL PI, 0.1% sodium citrate, 0.1%
Triton X-100, and 1 mg/mL RNase A (Roche, Basel, Switzerland)] in PBS for
20 minutes at 4jC. Later, cells were analyzed by flow cytometry, and the
sub-G0/G1 fraction was measured using the Lysis program (Becton
Dickinson, Franklin Lakes, NJ). The percentage of cells undergoing specific
apoptosis was calculated by subtracting the percentage of cells that had
undergone spontaneous apoptosis in the relevant controls from the total
percentage of apoptotic cells in the study cultures.
Western blot analysis of phosphorylated epidermal growth factor
receptor/epidermal growth factor receptor, phosphorylated vascular
endothelial growth factor receptor 2/vascular endothelial growth
factor receptor, phosphorylated Akt/Akt, and phosphorylated mito-
gen-activated protein kinase/mitogen-activated protein kinase in
follicular thyroid carcinoma. The ability of AEE788 to inhibit EGF-
induced tyrosine phosphorylation of EGFR, VEGFR, MAPK, and Akt was
determined in the human WRO FTC cell line. Under serum-free conditions,
the WRO cells showed a low level of autophosphorylation that was
enhanced after exposure to recombinant human EGF for 15 minutes. Cells
were plated onto a six-well plate at a concentration of 4  105 cells per well
and incubated in 10% FBS medium overnight. The next day, the cells were
washed and incubated with serum-free medium for 24 hours. The study
wells were treated with AEE788 at a concentration of 0.01 to 5 Amol/L,
whereas the control wells were treated with DMSO for 1 hour. Then, cells
were activated with recombinant human EGF (40 ng/mL) for 15 minutes,
washed with PBS, and scraped with lysis buffer as described previously (31).
The proteins (70 Ag) were resolved on 10% SDS-PAGE and transferred onto
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0.45 mmol/L polyvinylidene difluoride membranes. The membranes were
probed overnight with the desired primary antibodies. After incubation with
appropriate secondary antibodies, signals were visualized by the Super-
Signal West Pico Chemiluminescent system from Pierce (Rockford, IL).
PCR analysis of epidermal growth factor receptor mutations. To
determine whether the WRO cell line harbors EGFR mutations that might
render it more sensitive to AEE788, PCR analysis was used to amplify exons
18, 19, and 21 from the human EGFR gene by using genomic DNA isolated
from the WRO cell line. The sequences of PCR primers are the same as the
ones reported previously (35). PCR amplicons were purified using QIAquick
PCR purification kit (Qiagen, Valencia, CA) and sent for sequencing. The
sequencing results were then blasted and compared with the wild-type
EGFR sequence from Genbank.
Injection of WRO cells into the tibia of nude mice.Male athymic nude
mice were purchased from the animal production area of the National
Cancer Institute-Frederick Cancer Research Facility (Frederick, MD) and
maintained in specific pathogen-free barrier animal facilities approved by
the American Association for Accreditation of Laboratory Animal Care.
They were used for experiments at ages 8 to 12 weeks. To produce bone
tumors, WRO cells were harvested from subconfluent cultures by a 2-
minute exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization was
stopped with medium containing 10% FBS, and the cells were washed once
in serum-free medium and resuspended in Ca2+- and Mg2+-free HBSS. Nude
mice were anesthetized with i.p. sodium pentobarbital (commonly known
as Nembutal; Abbott Laboratories, North Chicago, IL) at a 50 mg/kg
concentration. A percutaneous intraosteal injection was made by drilling a
27-gauge needle into the tibia immediately proximal to the tuberositas
tibiae. After penetration of the cortical bone, the needle was inserted into
the shaft of the tibia, and 20 AL of the cell suspension (4  105 cells) were
deposited in the bone cortex using a calibrated, pushbutton-controlled
dispensing device (Hamilton Syringe Co., Reno, NV). To prevent leakage of
cells into the surrounding muscles, a cotton swab was held for 1 minute
over the site of injection. The animals tolerated the surgical procedure well,
and no anesthesia-related deaths occurred.
Therapy for human follicular thyroid carcinoma cells growing in
the tibia of athymic nude mice. Three days after the intratibial injection
of the WRO cells, the nude mice were randomized into four groups (n = 13):
(a) the control group received oral administrations of the vehicle solution
(90% polyethylene glycol 300 + 10% 1-methyl-2-pyrrolidinone) thrice weekly
and a once weekly i.p. injection of HBSS; (b) the paclitaxel group received an
i.p. injection of 200 Ag paclitaxel once weekly; (c) the AEE788 group received
oral administrations of 50 mg/kg AEE788 thrice weekly; and (d) the AEE788
plus paclitaxel group received 50 mg/kg AEE788 orally thrice weekly and
a once weekly i.p. injection of 200 Ag paclitaxel. The mice were treated for
5 weeks.
Digital radiography, tumor harvest, and tissue preparation. After 2,
3, 4, and 5 weeks of treatment, mice from all groups were anesthetized with
sodium pentobarbital and placed in a prone position. Digital radiography
was carried out using the Faxitron machine (Faxitron X-ray Corp., Wheeling,
IL; ref. 36). Tumor incidence and size were recorded. The mice were
euthanized by carbon dioxide inhalation on week 5 of the study (after 4
weeks of treatment) and weighed. Both legs were resected at the head of the
femur and weighed. The net tumor weight was calculated by subtracting the
weight of the uninjected leg from that of the leg with a tumor. The presence
of a tumor in bone was confirmed by histologic examination. Tumor tissues
were cut into 2 to 3 mm3 pieces that included the tibia and surrounding
muscles. The fragments were fixed in 10% buffered formalin for 24 hours at
room temperature, washed with PBS for 30 minutes, decalcified with 10%
EDTA (pH 7.4) for 7 to 10 days at 4jC, and then embedded in paraffin. The
method described by Mori et al. (37) was used for the preparation of frozen
sections with the following modifications: tumors cut into 2 to 3 mm3
pieces were fixed in periodate-lysine-paraformaldehyde solution (4%
paraformaldehyde containing 0.075 mol/L lysine and 0.01 mol/L sodium
periodate) for 24 hours, washed with PBS for 30 minutes, decalcified with
10% EDTA (pH 7.4) for 7 to 10 days, and washed thrice (once with PBS
containing 10% sucrose for 4 hours, once with PBS containing 15% sucrose
for 4 hours, and once with PBS containing 20% sucrose for 16 hours).
All procedures were carried out at 4jC. The tissues were then embedded in
OCT compound (Miles, Inc., Elkhart, IN), frozen rapidly in liquid nitrogen,
and stored at 80jC.
Immunohistochemical-immunofluorescent determination of epi-
dermal growth factor, vascular endothelial growth factor, epidermal
growth factor receptor, activated epidermal growth factor receptor,
vascular endothelial growth factor receptor, activated vascular
endothelial growth factor receptor, Akt, activated Akt, mitogen-
activated protein kinase, activated mitogen-activated protein kinase,
proliferating cell nuclear antigen, terminal deoxynucleotidyl transfer-
ase–mediated dUTP nick end labeling, and CD31/platelet/endothelial
cell adhesion molecule-1. To examine the activity of AEE788, tumor
specimens were processed for routine histologic and immunohistochemical
analyses for markers of vascularization, survival, proliferation, and cell
death. In vivo cell proliferation and apoptosis were evaluated using anti-
PCNA antibodies and terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling (TUNEL), respectively. Paraffin-embedded tissues
were used for identification of PCNA, EGF, VEGF, EGFR, and VEGFR2. The
sections were dried overnight, deparaffinized in xylene, and dehydrated in a
graded series of alcohol followed by rehydration in PBS. Sections analyzed
for PCNA and VEGFR2 were microwaved for 5 minutes for antigen retrieval,
whereas sections analyzed for VEGF and EGFR were incubated for 20
minutes with pepsin at 37jC for antigen retrieval as described previously.
Frozen tissues were used for identification of CD31/PECAM-1, activated
EGFR, activated VEGFR2, activated MAPK, activated Akt, and TUNEL.
The tissues were sectioned mounted and air dried for 30 minutes.
Frozen sections were fixed in cold acetone (5 minutes), 1:1 acetone/
chloroform (v/v; 5 minutes), and acetone (5 minutes) and washed with PBS.
Immunohistochemical procedures were done as described previously (34).
Control samples exposed to the secondary antibody alone showed no
specific staining.
Immunofluorescent double staining for CD31/activated epidermal
growth factor receptor, CD31/activated vascular endothelial growth
factor receptor 2, and CD31/terminal deoxynucleotidyl transferase–
mediated dUTP nick end labeling. To study the proposed antiangiogenic
effect of AEE788 and its potential ability to inhibit EGFR and VEGFR
phosphorylation on tumor-associated endothelial cells, periodate-lysine-
paraformaldehyde–fixed frozen tissues were sectioned and prepared as
mentioned above. Double staining (CD31/TUNEL, CD31/activated EGFR,
and CD31/activated VEGFR2) was done as follows: EGFR immunostaining
was done after CD31 staining. Samples were incubated with a protein-
blocking solution for 5 minutes with a 1:50 dilution of rabbit polyclonal
antihuman EGFR antibody (mouse cross-reactive) for 18 hours at 4jC.
Secondary goat anti-rabbit antibody conjugated to FITC was added for
1 hour. The samples were with Vectashield (Vector Laboratories,
Burlingame, CA). TUNEL assay was done using an apoptosis detection kit
(Promega, Madison, WI).
Immunofluorescence microscopy was done in a Nikon Microphot-FX
(Nikon, Inc., Garden City, NY) equipped with a HBO 100 mercury lamp and
narrow band-pass filters to individually select for green, red, and blue
fluorescence (Chroma Technology Corp., Brattleboro, VT). Images were
captured using a cooled charged coupled device Hamamatsu 5810 camera
(Hamamatsu Corp., Bridgewater, NJ) and Optimas Image Analysis software
(Media Cybernetics, Silver Spring, MD). Stained sections were examined in a
Nikon Microphot-FX microscope equipped with a three-chip charged
coupled device color video camera (model DXC990, Sony Corp., Tokyo,
Japan). Photomontages were prepared using Photoshop software (Adobe
Systems, Inc., San Jose, CA). Endothelial cells were identified by red
fluorescence staining, and DNA fragmentation was detected by localized
green and yellow fluorescence within the nuclei of apoptotic cells.
Photomontages were printed in a Sony digital color printer (model UP-
D7000).
Quantification of microvessel density, terminal deoxynucleotidyl
transferase–mediated dUTP nick end labeling, proliferating cell
nuclear antigen, epidermal growth factor, vascular endothelial growth
factor, epidermal growth factor receptor, and vascular endothelial
growth factor receptor. For the quantification analysis, five slides were
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prepared for each group, and two areas were selected in each slide. The
percentage of stained cells among the total number of cells in each area and
the average proportion of stained cells in each group were calculated and
compared. For total TUNEL and PCNA expression, the positive cells were
counted at 100 magnification and divided by total number of tumor cells
in 10 random 0.159-mm2 fields adjacent to bone. The PCNA+ cells were
counted in the randomly selected pure tumor area and the percentage is
reported as PCNA+ cells divided PCNA+ cells with the total number of
tumor cells. Quantification of apoptotic endothelial cells was expressed as
an average of the ratio of apoptotic endothelial cells to the total number of
endothelial cells in 10 random 0.011-mm2 fields at 400 magnification.
To quantify MVD, 10 random 0.159-mm2 fields adjacent to the bone at
100 magnification were captured for each tumor, and the mean number
of vessels was quantified as described previously (38).
For the quantification of immunohistochemical intensity, the absorbance
of 100 EGF+, VEGF+, EGFR+, and VEGFR+ cells in 10 random 0.039-mm2
fields at 200 magnification was taken from treated tumor tissues and was
measured using the Optimas Image Analysis software. The samples were
not counterstained so that the absorbance would be attributable solely to
the product of the immunohistochemical reaction. Immunoreactivity was
evaluated by computer-assisted image analysis and expressed as a density
value.
Statistical analysis. Descriptive statistics including means and SDs were
done. The Wilcoxon rank sum test was used to assess the effect of treatment
on tumor weight and other continuous measurements (CD31/PECAM-1,
CD31/TUNEL, TUNEL, and PCNA). Frequency tables were obtained by
cross-classifying the treatment group and the categorical outcome. The
incidence of bone lysis between different groups of mice was compared
using the Fisher’s exact test. All computations were carried out on a Dell
personal computer using SAS software (SAS Institute, Inc., Cary, NC) and
Excel 2000 (Microsoft, Redmond, WA) in a Windows NT operating system.
Results
High expression of epidermal growth factor receptor in
thyroid carcinoma cells. Although anaplastic thyroid cancer
constitutes only 1% of all thyroid tumors (3), it is among the most
aggressive and fatal of all neoplasms. Western blotting was used to
assess the level of all four members (HER1, HER2, HER3, and HER4)
of the EGFR family of receptors in a panel of thyroid cancer cell
lines. HER1, the most studied member of the EGFR family of
receptors and commonly called EGFR, was highly expressed in the
WRO cell line by comparison with the papillary thyroid cancer
NPA187 cell line and most of the anaplastic thyroid cancer cell lines
(Fig. 1A). Moreover, the WRO cells had the highest expression of
HER2 and HER4 receptors (Fig. 1A). No expression of HER3 was
detected in any of the thyroid cancer cell lines studied (data not
shown).
AEE788 inhibits the epidermal growth factor–induced
phosphorylation of epidermal growth factor receptor, vascular
endothelial growth factor receptor 2, Akt, and mitogen-
activated protein kinase in follicular thyroid carcinoma cells
growing in culture. Next, we determine whether AEE788 can
inhibit the EGF-mediated growth and survival signaling pathways
in FTC growing in culture. WRO cells were starved of serum
overnight, treated with increasing concentrations of AEE788 for
1 hour, and then stimulated with EGF for 15 minutes. Western blots
revealed that the inhibition of EGFR phosphorylation required
0.05 Amol/L, whereas complete abrogation of phosphorylated
VEGFR2 phosphorylation required 5 Amol/L AEE788 (Fig. 1B). The
phosphorylated forms of both Akt and MAPK were down-
modulated in cells treated with 0.5 Amol/L AEE788. Total levels
of EGFR, VEGFR, Akt, and MAPK remained unaltered by AEE788
treatment (Fig. 1B).
AEE788 suppresses the in vitro proliferation of follicular
thyroid carcinoma cells and sensitizes the cells to paclitaxel-
mediated cytotoxicity. The growth of the WRO cells in medium
containing 2% FBS was inhibited by AEE788 at an IC50 of 2.65
Amol/L (Fig. 2A). Furthermore, WRO cells exhibited paclitaxel-
mediated growth inhibition at an IC50 of 3.78 nmol/L (Fig. 2B),
which was amplified by the addition of 0.5 Amol/L AEE788
(i.e., lowering the IC50 from 3.78 to 2.67 nmol/L). The AEE788-
mediated increase in the sensitivity of the WRO cell line to
chemotherapy, however, was evident only at the lower concen-
trations of paclitaxel (Fig. 2B). To elucidate the importance of
EGFR versus VEGFR inhibition on proliferation, WRO cells were
treated with either an EGFR inhibitor (PKI166), a VEGFR
inhibitor (PTK787), or a combination of both (PKI166 +
PTK787). Cell growth was inhibited by PKI166 and PTK787
treatment alone at an IC50 of 4.26 and 9.12 Amol/L, respectively.
Figure 1. Expression of EGFR family members in thyroid cancer cell lines and
dose-dependent inhibition of EGFR and VEGFR signaling in WRO FTC cells
after treatment with AEE788. A, Western blotting was used to assess the level of
expression of the EGFR family of receptors in thyroid cancer cell lines. Blots
were additionally probed with anti-h-actin antibody for equal loading.
Representative of three independent experiments. B, autophosphorylation of
EGFR, VEGFR2, MAPK, and Akt was evaluated in WRO cells growing in vitro
in serum-free medium and stimulated with recombinant human EGF (40 ng/mL)
for 15 minutes in the presence or absence of AEE788. Western blotting was
done on protein extracts, and the membrane was later probed with anti-human
EGFR phosphorylated at Tyr1068 (pEGFR Y1068 ), VEGFR2 phosphorylated at
Tyr1045 (pVEGFR2 Y1054), MAPK phosphorylated at Thr42/Thr44 (pMAPK 42/44),
and Akt phosphorylated at Ser473 (pAKT S473 ). Total EGFR, VEGFR2, MAPK,
and Akt protein levels remained constant. h-Actin protein expression was used
as an internal probe for equal loading. Representative of three independent
experiments.
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When both drugs were combined at equal doses, WRO cell
proliferation was inhibited at an IC50 of 3.88 Amol/L (Fig. 2E).
AEE788 and paclitaxel induce apoptosis of follicular thyroid
carcinoma cells in vitro . Next, we analyzed the ability of AEE788
and paclitaxel to induce apoptosis in WRO cells. The cells were
incubated with increasing concentrations of each drug alone, and
apoptosis was determined by a flow cytometry–based assay. After
72 hours of treatment with AEE788, 50% of the cells underwent
apoptosis at 14.7 Amol/L. At 22 Amol/L, f80% cell death was
achieved (Fig. 2C). In parallel, paclitaxel induced apoptosis in the
Figure 2. Antiproliferative effects of AEE788 versus PKI166/PTK787 on the WRO human FTC cell line. MTT and flow cytometry–based assays were done to determine
the effects of AEE788 used alone or in combination with paclitaxel on the proliferation and apoptosis of cultured WRO FTC cells. Dose-dependent growth inhibition
of (A ) AEE788 alone, (B) AEE788 given with increasing doses of paclitaxel, PKI166, and PTK787 alone, or in combination (E). Points, average of at least three
experiments. AEE788 also induced apoptosis (C ) in a dose-dependent fashion with an IC50 of 14.7 Amol/L after 72 hours of treatment. Similarly, paclitaxel induced
apoptosis (D ) of WRO FTC cells with an IC50 approaching 16 nmol/L. PKI166 treatment alone induced dose-dependent cell death with an IC50 of 18 Amol/L,
whereas PTK787 alone did not induce high levels of apoptosis even at the highest dose tested (22 Amol/L). When combined, PKI166 + PTK787 showed an IC50 of
15.2 Amol/L (F ).
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WRO cells with an IC50 of 16 nmol/L (Fig. 2D). No sensitizing effect
of AEE788 (at 2 and 4 Amol/L) on the paclitaxel-induced apoptosis
of FTC cells was detected when both drugs were added
simultaneously (data not shown). When compared with AEE788
alone, PKI166 plus PTK787 combination induced comparable levels
of apoptosis with an IC50 of 15.2 Amol/L (Fig. 2F). PKI166 alone
achieved 50% of cell death at 18 Amol/L. On the other hand,
PTK787 alone failed to induce high levels of apoptosis even at the
highest dose tested (22 Amol/L).
PCR analysis of epidermal growth factor receptor shows no
mutations in the WRO cell line. Two recent studies have
suggested that the clinical responsiveness to therapies like
gefitinib—originally designed to target the phosphorylation of
EGFR in human lung cancer—is closely correlated with specific
mutations in exons 18, 19, and 21 of the human EGFR gene. Such
mutations led to increased growth factor signaling and conferred
susceptibility to inhibition by gefitinib (35). In light of the
susceptibility of WRO to AEE788 treatment, we investigated
whether such mutations also exist in this cell line. EGFR
mutational analysis did not find mutations in exons 18, 19, and
21 of the EGFR gene in the WRO cell line (data not shown).
The follicular thyroid carcinoma cells grow progressively
and induces osteoblastic and osteolytic bone lesions in nude
mice. To study the biology of bone metastases secondary to FTC, we
adopted the established murine model of bone lesions (15, 36, 39) by
injecting the WRO cells into the tibia of athymic nude mice followed
with weekly radiographic imaging. By the start of the third week,
early signs of bone lesions, as evidenced by thinning of the bone,
were evident (Fig. 3A). Bone lysis was visible by the fourth week; by
the fifth week, advanced bone destruction with marked erythema of
the overlying soft tissue was visible (Fig. 3A). This progressive bone
lysis over time was detected in 80% of the injected mice. H&E
staining of serial sections of the injected tibias revealed osteoblastic
and osteolytic lesions (Fig. 3B), which are common to FTC (10).
AEE788, alone and in combination with paclitaxel, inhibits
the growth of follicular thyroid carcinoma in the tibia of nude
mice. To assess the effect of AEE788 on the in vivo growth of
FTC cells in bone, the previously described mouse model was used
(15, 36, 39). Digital radiography of the injected tibias revealed that
80% of the mice in the control group had progressive bone lysis.
The incidence of lytic bone lesions in the mice treated with
paclitaxel was not significant (Table 1). As shown in Fig. 3C and D ,
severe bone lysis was detected in both the control and the
paclitaxel-treated groups. AEE788, as a single agent, did not
decrease tumor incidence but markedly reduced the extent of bone
lysis (Fig. 3C and D). AEE788 combined with paclitaxel significantly
reduced the incidence of bone lysis (45%; P < 0.05). In the mice
given oral AEE788 alone, bone integrity was maintained. The best
preservation of bone structure was in mice treated with the
AEE788 plus paclitaxel.
AEE788 treatment significantly reduced tumor weight compared
with control and paclitaxel-treated tumors (P < 0.05; Table 1). The
combination of paclitaxel plus AEE788 produced higher reduction
in bone lesions (P < 0.05; Table 1).
Histologic and immunohistochemical analyses. To assess the
extent of microscopic disease in the injected tibias, tumors were
processed for routine histology. H&E staining revealed the
presence of tumor cells within the medullary canal of the proximal
tibia, the extent of bone destruction, and the extravasation of
tumors into the surrounding soft tissues. The mice in the control
and paclitaxel-treated groups had extensive tumors, destruction of
the surrounding cortical bone, and extrusion of the WRO cells into
the surrounding soft tissues (Fig. 3D). In contrast, most tumors in
mice treated with AEE788 alone or with AEE788 plus paclitaxel
were much smaller, did not destroy the cortical bone architecture,
and were contained within the bone space (Fig. 3D).
AEE788 blocks epidermal growth factor receptor and
vascular endothelial growth factor receptor signaling in
follicular thyroid carcinoma cells growing in the bone.
Immunohistochemical studies revealed that the level of expression
of EGF, VEGF, EGFR, and VEGFR did not vary significantly among
tumors from all groups (Table 2; Fig. 4A). Conversely, the status of
EGFR and VEGFR activation differed markedly in tumors from the
mice treated with AEE788 alone and AEE788 plus paclitaxel in
comparison with the control and paclitaxel-treated mice. When
antibodies specific to tyrosine-phosphorylated (activated) EGFR
and VEGFR were used, both receptors showed high levels of
phosphorylation in the absence of AEE788 treatment. High levels of
phosphorylation were markedly reduced in tumors treated with
AEE788 alone and AEE788 plus paclitaxel (Fig. 4B).
The status of two of the major downstream targets of EGFR
and VEGFR pathways, Akt and MAPK, was also assessed by
immunohistochemical analysis. No change in the level of
expression of total Akt and MAPK proteins was evident in the
four groups (Fig. 5A). However, the phosphorylation status of
both kinases, although high in the control and paclitaxel-treated
tumors, was distinctly down-regulated in the mice treated with
AEE788 alone and AEE788 plus paclitaxel (Fig. 5A).
AEE788 arrests cell proliferation and induces apoptosis in
follicular thyroid carcinoma cells growing in bone. In addition
to the inhibition of EGFR and VEGFR signaling, the decrease in
tumor weight in mice treated with AEE788 and AEE788 plus
paclitaxel could have been due to a reduction in tumor cell
proliferation, increased tumor cell apoptosis, or a combination
of both.
To examine in vivo cell proliferation and apoptosis, antibodies
were used against PCNA and the TUNEL assay, respectively. As
shown in Fig. 4B , PCNA+ cells were mostly abundant in the control
group and decreased in the treated tumors. In addition, TUNEL+
cells were rarely detected in tumors from the control mice. A
progressive increase in the green fluorescent apoptotic cells was
found in the tumors from the treated mice.
The percentage of detected PCNA+ cells was significantly
reduced in the AEE788-treated groups, and the percentage was
lowest in the AEE788 plus paclitaxel group (P < 0.05; Table 2). The
percentage of dying cells in mice treated with AEE788 or AEE788
plus paclitaxel was significantly higher than in the control group
(P = 0.034; Table 2).
AEE788 suppresses angiogenesis by inhibiting epidermal
growth factor receptor and vascular endothelial growth
factor receptor phosphorylation and inducing apoptosis in
tumor-associated endothelial cells. When antibodies were used
against CD31 on the surface of endothelial cells, the MVD was
highest in the control group and paclitaxel-treated tumors
(Table 2). MVD was significantly (P < 0.05) decreased in the
tumors treated with AEE788 alone and AEE788 plus paclitaxel,
respectively (Table 2; Fig. 5B). Double staining for CD31/activated
EGFR and CD31/activated VEGFR—done with CD31 (red stain-
ing) and activated EGFR and activated VEGFR (green staining)—
revealed that only tumors from the mice treated with AEE788 and
AEE788 plus paclitaxel had decreased double staining (yellow
color) for these markers, a finding consistent with reduced
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signaling through EGFR and VEGFR in endothelial cells (Fig. 5B).
Finally, double staining for CD31 (red staining)/TUNEL (green
staining) showed that the percentage of apoptotic endothelial
cells (yellow staining) was significantly higher in the bone tumors
of mice treated with AEE788 alone and AEE788 plus paclitaxel
than in the control and those treated with paclitaxel alone (P <
0.05; Table 2; Fig. 5B).
Discussion
In our study, AEE788 and paclitaxel effectively inhibited cellular
proliferation and induced apoptosis of FTC growing in culture.
In addition, AEE788 suppressed the phosphorylation of EGFR,
VEGFR, Akt, and MAPK in FTC. In a mouse model for bone
lesions, WRO cells grew progressively and produced mainly
osteolytic and some osteoblastic lesions. The oral administration
of AEE788 alone, thrice weekly or in combination with once
weekly i.p. injections of paclitaxel, significantly reduced the
incidence and size of bone lesions and prevented bone lysis as
determined by digital radiography and confirmed by histologic
examination. Immunohistochemical analyses showed the in vivo
inhibition of activated EGFR and VEGFR signaling pathways and
downstream Akt and MAPK activities in WRO-induced bone
lesions from mice treated with AEE788 alone or in combination
with paclitaxel. Consequently, tumor cell proliferation (PCNA+
cells) was suppressed, and tumor cell apoptosis (TUNEL+ cells)
Figure 3. Effect of AEE788 on bone lesions secondary to FTC in a model for bone metastasis in nude mice. A, WRO cells were injected into the right tibia of athymic
nude mice. Bone lysis was detected (white arrows ) as early as the third week and progressed to severe cortical bone destruction by the end of 5 weeks. B, H&E
staining of bone tumors after the fifth week. Note the osteoblastic lesions (thin black arrows ) and osteolytic lesions (thick black arrows ) in comparison with normal
bone (right ). C and D, mice were segregated into four treatment groups. The mice in the control group and those treated with paclitaxel had large tumors with
extensions into the surrounding tissue. AEE788 alone or in combination with paclitaxel preserved the integrity of the cortical bone and maintained the tumor cells
within the bony space as seen by H&E staining.
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was induced. In addition, AEE788 alone and in combination with
paclitaxel silenced the EGFR and VEGFR signaling on the surface
of tumor-associated endothelial cells. In response, endothelial
cells (TUNEL+/CD31+ cells) underwent apoptosis, leading to a
significant reduction in MVD.
In vitro , AEE788 alone showed enhanced growth inhibition of
WRO cells compared with PKI166 plus PTK787 combination. This
may be attributed to the fact that AEE788, in addition to its primary
inhibition of EGFR and VEGFR pathways, can also inhibit c-Src, c-
kit, and RET pathways at higher doses (30). All three pathways have
been shown to play a pivotal role in the tumorigenesis of thyroid
carcinomas (40). PTK787 treatment alone did not induce high levels
of apoptosis and high doses of PTK787 were needed to induce cell
growth inhibition. This suggests that the effect of AEE788, at least
in vitro , is mainly attributable to inhibition of EGFR. Although
inhibition of the VEGFR is seen in tumor cells in vitro , this does not
seem to have an effect on tumor cell survival or proliferation, as
does inhibition of the EGFR, and highlights the importance of
testing this compound in vivo to determine the effect of VEGFR
inhibition. Whereas EGFR is seen to localize to the endothelia and
tumor cells, the inhibition of VEGFR kinase activity is thought to
contribute to endothelial cell apoptosis and decreased MVD with
resultant increase in tumor cell apoptosis.
Our present results closely agree with our previous work (41)
and other studies (42) reporting that EGFR is overexpressed in
differentiated and anaplastic thyroid carcinomas and that targeting
EGFR by anti-EGFR antibodies (EGFR antibody 528) completely
neutralized the EGF-mediated stimulation of FTC cell growth and
invasion in culture (19). Furthermore, our findings agree with studies
showing that genistein, a general tyrosine kinase antagonist, can
abrogate growth stimulation of EGF and transforming growth
factor-a (TGF-a) on invasion and growth of FTC cells (19).
At present, our data have shown that radiographically there
was a significant reduction in bone destruction in mice treated
with AEE788 alone or with AEE788 plus paclitaxel. One possible
explanation is that TGF-a and EGF increased the proliferation of
osteoclast precursors, thus inducing a surge in the number of
osteoclasts leading to bone lysis. Blockade of EGFR signaling by
Table 1. Results of treatment with AEE788 and paclitaxel for human FTC growing in the bones of nude mice
Treatment groups* Lytic lesion incidence (%)
c
Tumor weight (g), median (range)
Control 8/10 (80) 0.29 (0.074-0.547)
Paclitaxel 8/9 (89) 0.375 (0.175-2.484)
AEE788 7/8 (88) 0.118
b
(0.011-0.253)
AEE788 + paclitaxel 5/11 (45) 0.048
b
(0.004-1.377)
*WRO human FTC cells (4  105) were injected into the tibia of nude mice. Three days later, groups of mice were randomized into four groups: i.p.
injections of paclitaxel (200 Ag) alone (once weekly), oral feedings of AEE788 (500 mg/kg) alone (thrice weekly), paclitaxel in combination with AEE788,
or placebo (control). All mice were killed after 5 weeks of treatment.
cNumber of mice with lytic lesions visualized by digital radiography divided by the number of mice injected.
bP < 0.05, compared with controls (Wilcoxon rank sum test).
Table 2. Quantitative immunohistochemical analysis of WRO human FTC tumors growing in the tibia of nude mice
Variable Treatment groups
Control Paclitaxel AEE788 AEE788 + paclitaxel
Tumor cells
PCNA* 21.55 F 2.95 15.12 F 3.81 9.17 F 1.89c 6.63 F 2.37c
TUNEL* 6.76 F 2.72 14.08 F 6.5 44.12 F 14.64c 54.89 F 14.07c
EGF (absorbance)
b
0.94 F 0.33 0.88 F 0.30x 1.1 F 0.35x 0.89 F 0.25x
VEGF (absorbance)
b
1.23 F 0.45 1.20 F 0.44x 1.35 F 0.46x 1.33 F 0.48x
EGFR (absorbance)
b
0.31 F 0.18 0.33 F 0.1x 0.42 F 0.11x 0.36 F 0.11x
VEGFR (absorbance)
b
0.52 F 0.17 0.6 F 0.14x 0.55 F 0.17x 0.69 F 0.10x
Endothelial cells
CD31* 12.62 F 3.66 11 F 3.77 5.79 F 1.49c 6.13 F 2.09c
CD31/TUNELk 1 (0-3) 2 (0-3) 12 (6-19)
c
16 (9-25)
c
*Mean F SD, ratio of positive cells to total tumor/endothelial cells, as determined from measurement of 10 random 0.159-mm2 fields at 100
magnification.
cP < 0.05 (Wilcoxon rank sum test).
bAbsorbance determined as described in Materials and Methods.
xP > 0.05 (Wilcoxon rank sum test).
kMedian of the ratio of apoptotic endothelial cells to total number of endothelial cells in 10 random 0.011-mm2 fields at  400 magnification.
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AEE788 may therefore decrease the number and activity of
osteoclasts (43).
In our study and others (44), the active phosphorylated forms of
VEGFR2 receptors were not found on the endothelial cells in the
uninjected leg (data not shown). Moreover, we have shown that
VEGFR2 was expressed in both the FTC cells and the tumor-
associated endothelial cells. VEGFR2 phosphorylation was inhibited
by treatment with AEE788 treatment under in vitro and in vivo
conditions. PTK787 has shown antitumoral and antiangiogenic
activity against FTC xenografts (28). Furthermore, soluble VEGF
receptor (sFlt-1) gene therapy effectively reduced the growth of FTC
xenografts (27). Mice treated with an anti-VEGF antibody (mono-
clonal antibody 4.6.1) develop smaller FTC tumors containing few
blood vessels (21). Furthermore, endostatin protein and gene
therapy have proven to be effective in suppressing the growth of
FTC xenografts (29). Collectively, the down-modulation of VEGF
signaling can produce inhibition of differentiated thyroid cancer
growth in vivo .
Increased vascularity has been reported in thyroid tumors (45). In
thyroid cancer, increased MVD has been correlated with decreased
disease-free survival (28). Similarly, MVD in the areas of the most
intense vascularization is an independent prognostic factor in
patients with breast and non–small cell lung cancer (46, 47). In our
study, oral administration of AEE788 alone or in combination with
paclitaxel significantly decreased MVD. Most endothelial cells in
normal tissues and organs are quiescent and do not divide. In
contrast, endothelial cells in many tumors are dividing. Proliferating
endothelial cells have been shown to express low levels of EGFR (34).
In our study, only the tumor-associated endothelial cells from the
mice treated with AEE788 alone or in combination with paclitaxel
Figure 4. Dual inhibition of EGFR and
VEGFR phosphorylation and increased
tumor apoptosis in FTC-induced bone
lesions after treatment with AEE788 alone
or in combination with paclitaxel. Bone
tumors of the WRO FTC cells that have
been injected into the tibia of nude mice
were harvested and processed for
immunohistochemical analysis after the
fifth week of treatment with HBSS and
AEE788 vehicle (control), once weekly i.p.
injection of paclitaxel (200 Ag once
weekly), thrice weekly oral administration
of AEE788 (50 mg/kg), or a combination of
both regimens. A, immunohistochemical
analysis using specific anti-EGF,
anti-VEGF, anti-EGFR, and anti-VEGFR
antibodies showed that WRO tumors from
all four treatment groups exhibited similar
levels of EGF, VEGF, EGFR, and VEGFR.
B, specific antibodies to phosphorylated
EGFR and phosphorylated VEGFR were
used to assess the activation status of
these receptors. The tumors from mice
treated with AEE788 alone or in
combination with paclitaxel showed
diminished phosphorylation of EGFR and
VEGFR in comparison with tumors
from nontreated (control group) and
paclitaxel-treated mice. Tumors from all
four groups were also stained for PCNA
and TUNEL. Treatment with AEE788, with
or without paclitaxel, reduced expression
of PCNA (brown staining ) and increased
apoptosis as marked by TUNEL+ cells
(green fluorescent staining ). Magnification,
100.
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had reduced double staining for CD31/activated EGFR and CD31/
activated VEGFR. Thus, it is possible that FTC cells stimulate EGFR
activation in endothelial cells by a paracrinemechanism through the
production of EGF and possibly TGF-a. The loss of major survival
signals in endothelial cells might render them more susceptible to
taxane-based therapy. Crippling such vital signaling pathways and
inducing apoptosis in endothelial cells can create a second wave of
apoptosis in the adjacent tumor cells. This is in agreement with a
study in which paclitaxel was found to enhance the antitumor
efficacy of DC101, a VEGFR2-blocking antibody, by potentiating the
antiangiogenic response and inducing tumor and endothelial cell
apoptosis (48).
Despite the significant reduction in tumor size and incidence of
bone lysis in the groups of mice treated with AEE788 and paclitaxel,
55% of the animals exhibited bone lysis on digital radiography. It has
been postulated that blocking the EGFR signaling pathway reduced
activator protein-1 activity and hence the transcription of VEGF (34).
In our study, no reduction in VEGF expression could be detected by
immunohistochemical analysis in tumors from either group of mice
treated with AEE788. One possible explanation for the apparent
discrepancy is that VEGF expression in thyroid carcinomas is
regulated by additional growth factors, including insulin-like growth
factor-I (IGF-I; ref. 49). In fact, IGF-I is produced by stromal cells in
the microenvironment of thyroid carcinomas (50), promotes
proliferation (51), and suppresses apoptosis (52) of thyroid
carcinoma cells. These observations coupled with the fact that
IGF-I receptor is expressed on the surface of thyroid tumors (53) give
FTC an alternative route for growth and progression.
The phosphorylation status of two major downstream targets of
EGFR and VEGFR pathways, Akt and MAPK, was down-regulated in
FTC tumors growing in bone after AEE788 treatment. This finding is
in agreement with previous studies. Basically, the expression of all
Figure 5. Inhibition of downstream
kinase phosphorylation in tumors and
suppression of angiogenesis as
determined by reduction in MVD, inhibition
of receptor phosphorylation, and induction
apoptosis after treatment with AEE788.
A, WRO tumors growing in the tibia of mice
were stained for activated Akt (Act-Akt ),
total Akt, activated MAPK (Act-MAPK ),
and total MAPK. Although tumors from all
four groups showed similar patterns of
expression for total Akt and MAPK, tumors
from mice treated with AEE788 alone or in
combination with paclitaxel had a marked
reduction in the level of Akt and MAPK
phosphorylation compared with the control
and paclitaxel-treated tumors. B, MVD
status was assessed using antibodies
against CD31/PECAM-1 (red staining ). In
mice treated with AEE788 with or without
paclitaxel, CD31/PECAM-1 reduction
was noted. Double staining for CD31
(red)/TUNEL (green ) revealed induction of
apoptosis in tumor-associated endothelial
cells in both AEE788-treated tumors
(yellow staining ). Double staining for
CD31/activated EGFR (Act-EGFR ) and
CD31/activated VEGFR (Act-VEGFR2 )
was done with CD31 (red staining ) and
with activated EGFR and activated
VEGFR (green staining ). Suppression of
the phosphorylation of EGFR and VEGFR
on the surface of endothelial cells (marked
by the absence of yellow color ) was
detected only in the AEE788-treated
tumors with or without paclitaxel
administration. Magnification, 400.
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three isoforms of Akt are expressed in FTC (54). More importantly,
increased levels of phosphorylated Akt were higher in FTC than in
normal thyroid tissue (55). FTC cells invading the thyroid capsule or
blood vessels, or metastasizing to other areas, have been character-
ized by activation of Akt in a nuclear pattern, suggesting an
association between Akt activity and progression of tumors (54). Our
laboratory has shown that the inhibition of Akt phosphorylation by a
novel Akt inhibitor successfully suppressed cellular growth and
induced apoptosis in thyroid cancer cells (56).
Another important molecule that has been found to be up-
regulated in patients with bone metastasis from FTC is MAPK
(57). The RAS-RAF-extracellular signal-regulated kinase (ERK)-
MAPK/ERK kinase-MAPK pathway is of particular importance in
FTC tumorigenesis because of the higher prevalence of activating
mutations of all three Ras genes (58). Total MAPK was detected in
equal amounts in both tumors and normal tissues of the thyroid,
whereas phosphorylated MAPK was more prevalent in thyroid
tumors than in adjacent normal thyroid tissue (59). U0126, a
MAPK/ERK kinase-1/2 inhibitor, decreased phosphorylated MAPK
and reduced the cell viability of FTC cells in vitro (59).
Collectively, our results provide experimental evidence that
AEE788 can block bone lesions induced by FTC by inhibiting the
EGFR pathway on FTC cells and inhibiting angiogenesis by
suppressing the VEGFR signaling pathway in tumor-associated
endothelial cells. Our present findings closely agree with our
previous work that showed that dual blockade of EGFR and
VEGFR signaling with AEE788 inhibits the growth of human
squamous cell carcinoma of the oral cavity (31) and squamous
cell carcinoma of the skin in nude mice and produces apoptosis
of tumor-associated endothelial cells (60).
In summary, we show that the simultaneous blockade of
EGFR and VEGFR signaling by AEE788 alone or in combination
with paclitaxel can significantly reduce tumor size and
subsequent bone destruction by FTC in the bone of nude mice
mediated by both direct antitumor and antiangiogenic effects.
These data strongly recommend further development of AEE788
for clinical use in the treatment of FTC patients with bone
metastases.
Acknowledgments
Received 11/23/2004; revised 3/9/2005; accepted 3/31/2005.
Grant support: Golfers against Cancer and The University of Texas M.D. Anderson
Cancer Center Specialized Programs of Research Excellence in Head and Neck Cancer
grant P50 CA97007.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Sandy Young for editorial review and Patricia A. Phillips for expert
assistance in the submission of the article.
References
1. Correa P, Chen VW. Endocrine gland cancer. Cancer
1995;75:338–52.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics,
2004. CA Cancer J Clin 2004;54:8–29.
3. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501–11.
4. Hundahl SA, Cady B, Cunningham MP, et al. Initial
results from a prospective cohort study of 5583 cases
of thyroid carcinoma treated in the United States
during 1996. U.S. and German Thyroid Cancer Study
Group. An American College of Surgeons Commission
on Cancer Patient Care Evaluation Study. Cancer 2000;
89:202–17.
5. Lin JD, Huang MJ, Juang JH, et al. Factors related to
the survival of papillary and follicular thyroid carcino-
ma patients with distant metastases. Thyroid 1999;9:
1227–35.
6. Schlumberger MJ. Papillary and follicular thyroid
carcinoma. N Engl J Med 1998;338:297–306.
7. Schlumberger M, Tubiana M, De Vathaire F, et al.
Long-term results of treatment of 283 patients with
lung and bone metastases from differentiated thyroid
carcinoma. J Clin Endocrinol Metab 1986;63:960–7.
8. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH.
Morbidity and mortality in follicular thyroid cancer.
J Clin Endocrinol Metab 1995;80:2946–53.
9. Marcocci C, Pacini F, Elisei R, et al. Clinical and biologic
behavior of bone metastases from differentiated thyroid
carcinoma. Surgery 1989;106:960–6.
10. Roodman GD. Mechanisms of bone metastasis.
N Engl J Med 2004;350:1655–64.
11. Tubiana M, Haddad E, Schlumberger M, Hill C,
Rougier P, Sarrazin D. External radiotherapy in thyroid
cancers. Cancer 1985;55:2062–71.
12. Smit JW, Vielvoye GJ, Goslings BM. Embolization for
vertebral metastases of follicular thyroid carcinoma.
J Clin Endocrinol Metab 2000;85:989–94.
13. Menzel C, Grunwald F, Schomburg A, et al. ‘‘High-
dose’’ radioiodine therapy in advanced differentiated
thyroid carcinoma. J Nucl Med 1996;37:1496–503.
14. Dinneen SF, Valimaki MJ, Bergstralh EJ, et al. Distant
metastases in papillary thyroid carcinoma: 100 cases
observed at one institution during 5 decades. J Clin
Endocrinol Metab 1995;80:2041–5.
15. Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler
IJ. Blockade of epidermal growth factor receptor
signaling leads to inhibition of renal cell carcinoma
growth in the bone of nude mice. Cancer Res 2003;63:
2940–7.
16. Tuttle M, Robbins R, Larson SM, Strauss HW.
Challenging cases in thyroid cancer: a multidisciplin-
ary approach. Eur J Nucl Med Mol Imaging 2004;31:
605–12.
17. Zettinig G, Fueger BJ, Passler C, et al. Long-
term follow-up of patients with bone metastases
from differentiated thyroid carcinoma-surgery or
conventional therapy? Clin Endocrinol (Oxf) 2002;
56:377–82.
18. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR. Co-
expression of the genes encoding transforming growth
factor-a and its receptor in papillary carcinomas of the
thyroid. Int J Cancer 1990;46:382–7.
19. Holting T, Siperstein AE, Clark OH, Duh QY.
Epidermal growth factor (EGF)- and transforming
growth factor a-stimulated invasion and growth of
follicular thyroid cancer cells can be blocked by
antagonism to the EGF receptor and tyrosine kinase
in vitro . Eur J Endocrinol 1995;132:229–35.
20. Gorgoulis V, Aninos D, Priftis C, et al. Expression of
epidermal growth factor, transforming growth factor-a
and epidermal growth factor receptor in thyroid
tumors. In vivo 1992;6:291–6.
21. Soh EY, Eigelberger MS, Kim KJ, et al. Neutralizing
vascular endothelial growth factor activity inhibits
thyroid cancer growth in vivo . Surgery 2000;128:
1059–65;discussion 1065–56.
22. Hanahan D, Folkman J. Patterns and emerging
mechanisms of the angiogenic switch during tumori-
genesis. Cell 1996;86:353–64.
23. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial
growth factor expression is higher in differentiated
thyroid cancer than in normal or benign thyroid. J Clin
Endocrinol Metab 1997;82:3741–7.
24. Bunone G, Vigneri P, Mariani L, et al. Expression of
angiogenesis stimulators and inhibitors in human
thyroid tumors and correlation with clinical patholog-
ical features. Am J Pathol 1999;155:1967–76.
25. Tuttle RM, Fleisher M, Francis GL, Robbins RJ. Serum
vascular endothelial growth factor levels are elevated in
metastatic differentiated thyroid cancer but not in-
creased by short-term TSH stimulation. J Clin Endo-
crinol Metab 2002;87:1737–42.
26. Ishiwata T, Iino Y, Takei H, Oyama T, Morishita Y.
Tumor angiogenesis as an independent prognostic
indicator in human papillary thyroid carcinoma. Oncol
Rep 1998;5:1343–8.
27. Ye C, Feng C, Wang S, et al. sFlt-1 gene therapy of
follicular thyroid carcinoma. Endocrinology 2004;145:
817–22.
28. Schoenberger J, Grimm D, Kossmehl P, Infanger M,
Kurth E, Eilles C. Effects of PTK787/ZK222584, a
tyrosine kinase inhibitor, on the growth of a poorly
differentiated thyroid carcinoma: an animal study.
Endocrinology 2004;145:1031–8.
29. Ye C, Feng C, Wang S, Liu X, Lin Y, Li M.
Antiangiogenic and antitumor effects of endostatin on
follicular thyroid carcinoma. Endocrinology 2002;143:
3522–8.
30. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual
family epidermal growth factor receptor/ErbB2 and
vascular endothelial growth factor receptor tyrosine
kinase inhibitor with antitumor and antiangiogenic
activity. Cancer Res 2004;64:4931–41.
31. Yigitbasi OG, Younes MN, Doan DD, et al. Tumor and
endothelial cell therapy of oral cancer by dual tyrosine
receptor blockade. Cancer Res 2004;64:7977–84.
32. Estour B, Van Herle AJ, Juillard GJ, et al. Character-
ization of a human follicular thyroid carcinoma cell line
(UCLA RO 82 W-1). Virchows Arch B Cell Pathol Incl
Mol Pathol 1989;57:167–74.
33. Holsinger FC, Doan DD, Jasser SA, et al. Epidermal
growth factor receptor blockade potentiates apoptosis
mediated by paclitaxel and leads to prolonged survival
in a murine model of oral cancer. Clin Cancer Res
2003;9:3183–9.
34. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade
of the epidermal growth factor receptor signaling by a
novel tyrosine kinase inhibitor leads to apoptosis of
endothelial cells and therapy of human pancreatic
carcinoma. Cancer Res 2000;60:2926–35.
35. Lynch TJ, Bell DW, Sordella R, et al. Activating
mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer
to gefitinib. N Engl J Med 2004;350:2129–39.
Cancer Research
Cancer Res 2005; 65: (11). June 1, 2005 4726 www.aacrjournals.org
Research. 
on April 14, 2017. © 2005 American Association for Cancercancerres.aacrjournals.org Downloaded from 
36. Kim SJ, Uehara H, Yazici S, et al. Simultaneous
blockade of platelet-derived growth factor-receptor and
epidermal growth factor-receptor signaling and sys-
temic administration of paclitaxel as therapy for human
prostate cancer metastasis in bone of nude mice.
Cancer Res 2004;64:4201–8.
37. Mori S, Sawai T, Teshima T, Kyogoku M. A new
decalcifying technique for immunohistochemical stud-
ies of calcified tissue, especially applicable to cell
surface marker demonstration. J Histochem Cytochem
1988;36:111–4.
38. Baker CH, Solorzano CC, Fidler IJ. Blockade of
vascular endothelial growth factor receptor and epi-
dermal growth factor receptor signaling for therapy of
metastatic human pancreatic cancer. Cancer Res 2002;
62:1996–2003.
39. Uehara H, Kim SJ, Karashima T, et al. Effects of
blocking platelet-derived growth factor-receptor signal-
ing in a mouse model of experimental prostate cancer
bone metastases. J Natl Cancer Inst 2003;95:458–70.
40. Inaba M, Umemura S, Satoh H, et al. Expression of
RET in follicular cell-derived tumors of the thyroid
gland: prevalence and implication of morphological
type. Pathol Int 2003;53:146–53.
41. Schiff B, McMurphy A, Jasser S, et al. Epidermal
growth factor receptor (EGF-R) is overexpressed in
anaplastic thyroid cancer, and the EGF-R inhibitor
gefitinib (‘‘Iressa,’’ ZD 1839) inhibits the growth of
anaplastic thyroid cancer. Clin Cancer Res 2004;10:
8594–602.
42. Bergstrom JD, Westermark B, Heldin NE. Epidermal
growth factor receptor signaling activates met in
human anaplastic thyroid carcinoma cells. Exp Cell
Res 2000;259:293–9.
43. Roodman GD. Biology of osteoclast activation in
cancer. J Clin Oncol 2001;19:3562–71.
44. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion
JJ, Fidler IJ. Blockade of epidermal growth factor
receptor signaling in tumor cells and tumor-associated
endothelial cells for therapy of androgen-independent
human prostate cancer growing in the bone of nude
mice. Clin Cancer Res 2003;9:1200–10.
45. Ramsden JD. Angiogenesis in the thyroid gland.
J Endocrinol 2000;166:475–80.
46. Weidner N, Semple JP, Welch WR, Folkman J. Tumor
angiogenesis and metastasis-correlation in invasive
breast carcinoma. N Engl J Med 1991;324:1–8.
47. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis
as a prognostic indicator of survival in non-small-cell
lung carcinoma: a prospective study. J Natl Cancer Inst
1997;89:881–6.
48. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel
enhances the effects of the anti-epidermal growth
factor receptor monoclonal antibody ImClone C225 in
mice with metastatic human bladder transitional cell
carcinoma. Clin Cancer Res 2000;6:4874–84.
49. Poulaki V, Mitsiades CS, McMullan C, et al.
Regulation of vascular endothelial growth factor
expression by insulin-like growth factor I in thyroid
carcinomas. J Clin Endocrinol Metab 2003;88:5392–8.
50. Vella V, Sciacca L, Pandini G, et al. The IGF system
in thyroid cancer: new concepts. Mol Pathol 2001;54:
121–4.
51. Saito J, Kohn AD, Roth RA, et al. Regulation of FRTL-
5 thyroid cell growth by phosphatidylinositol (OH) 3
kinase-dependent Akt-mediated signaling. Thyroid
2001;11:339–51.
52. Mitsiades CS, Poulaki V, Mitsiades N. Insulin-like
growth factor (IGF)-1 protects thyroid carcinoma cells
from TRAIL-induced apoptosis. Proc Am Assoc Cancer
Res 2001;42:272.
53. Yashiro T, Ohba Y, Murakami H, et al. Expression of
insulin-like growth factor receptors in primary human
thyroid neoplasms. Acta Endocrinol (Copenh) 1989;121:
112–20.
54. Vasko V, Saji M, Hardy E, et al. Akt activation and
localisation correlate with tumour invasion and onco-
gene expression in thyroid cancer. J Med Genet 2004;41:
161–70.
55. Ringel MD, Hayre N, Saito J, et al. Overexpression and
overactivation of Akt in thyroid carcinoma. Cancer Res
2001;61:6105–11.
56. Mandal M, Younes MN, Jasser SA, El-Naggar AK,
Mills GB,Myers JN. The Akt inhibitor KP372-1 suppresses
Akt activity and cell proliferation and induces apoptosis
in thyroid cancer cells. Br J Cancer. In press 2005.
57. Chen KT, Lin JD, Chao TC, et al. Identifying
differentially expressed genes associated with metasta-
sis of follicular thyroid cancer by cDNA expression
array. Thyroid 2001;11:41–6.
58. Lemoine NR, Mayall ES, Wyllie FS, et al. High
frequency of ras oncogene activation in all stages
of human thyroid tumorigenesis. Oncogene 1989;4:
159–64.
59. Specht MC, Barden CB, Fahey TJ III. p44/p42-MAP
kinase expression in papillary thyroid carcinomas.
Surgery 2001;130:936–40.
60. Park YW, Younes MN, Jasser SA, et al. AEE788, a dual
tyrosine kinase inhibitor of EGFR and VEGFR, induces
endothelial cell apoptosis in human cutaneous squa-
mous cell carcinoma xenografts in nude mice. Clin
Cancer Res 2005;11:1963–73.
Inhibition of EGFR and VEGFR in FTC Bone Metastasis
www.aacrjournals.org 4727 Cancer Res 2005; 65: (11). June 1, 2005
Research. 
on April 14, 2017. © 2005 American Association for Cancercancerres.aacrjournals.org Downloaded from 
2005;65:4716-4727. Cancer Res 
  
Maher Nabil Younes, Orhan Gazi Yigitbasi, Young Wook Park, et al. 
  
Receptor Phosphorylation
Growth Factor Receptor and Vascular Growth Factor
Experimental Bone Metastasis by Blockade of Epidermal 
Antivascular Therapy of Human Follicular Thyroid Cancer
  
Updated version
  
 http://cancerres.aacrjournals.org/content/65/11/4716
Access the most recent version of this article at:
  
  
  
  
  
Cited articles
  
 http://cancerres.aacrjournals.org/content/65/11/4716.full.html#ref-list-1
This article cites 58 articles, 21 of which you can access for free at:
  
Citing articles
  
 /content/65/11/4716.full.html#related-urls
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
.permissions@aacr.orgDepartment at
To request permission to re-use all or part of this article, contact the AACR Publications
Research. 
on April 14, 2017. © 2005 American Association for Cancercancerres.aacrjournals.org Downloaded from 
